Your AI-Trained Oncology Knowledge Connection!
The addition of bevacizumab to erlotinib continued to provide a significant progression-free survival benefit over erlotinib alone when used in the frontline treatment of patients with EGFR-mutated, nonsquamous non–small cell lung cancer, according to data from the final analysis of the phase 3 BEVERLY trial.
Regorafenib did not show a benefit with progression-free survival in patients with advanced or metastatic chordoma.
Treatment with acalabrutinib as monotherapy or in combination with obinutuzumab improved quality-adjusted survival compared with chlorambucil plus obinutuzumab in patients with treatment-naïve chronic lymphocytic leukemia.
The median real-world progression-free survival with durvalumab was higher compared with the median progression-free survival reported in the durvalumab arm of the phase 3 PACIFIC trial in patients with stage III non–small cell lung cancer.
Fam-trastuzumab deruxtecan-nxki led to improved responses in patients with higher HER2 expression at baseline, whereas responses were seen irrespective of RAS- and PIK3CA mutation status and blood tumor mutational burden levels in patients with HER2-positive, metastatic colorectal cancer.
Meghan Thompson, MD, discusses the results of the phase 1/2 BRUIN study in patients with Richter transformation.
Tadeusz Robak, MD, PhD, discusses the results of the 7-year follow-up analysis of the phase 3 RESONATE-2 trial in chronic lymphocytic leukemia.
Adavosertib demonstrated a 65% reduction in the risk of disease progression or death compared with active monitoring in patients with TP53-/RAS-mutant metastatic colorectal cancer following first-line chemotherapy.
The addition of durvalumab to platinum/etoposide chemotherapy continued to demonstrate an overall survival benefit over chemotherapy alone with a favorable safety profile in patients with extensive-stage small cell lung cancer.
Giredestrant resulted in a greater relative reduction in Ki67 score from baseline to week 2 of a window of opportunity phase vs anastrozole in patients with estrogen receptor–positive, HER2-negative early breast cancer, according to results from an interim analysis of the phase 2 coopERA Breast Cancer trial.
Personalized medicine has come to the forefront of breast cancer management, with genomic tools being utilized to avoid unnecessary chemotherapy in those with early-stage disease, PARP and PI3K inhibitors improving outcomes for those who harbor select mutations, and the emergence of highly active targeted agents shaking up the HER2-positive paradigm.
During the XIX International Workshop on Chronic Lymphocytic Leukemia, which occurred virtually 17-20 September, Dr. John Byrd was presented the Binet-Rai Medal Award for his outstanding findings, which led to the use of BTK Inhibitors in almost every phase of CLL therapy.
Sitravatinib, a spectrum-selective TKI targeting TAM receptors and VEGFR2, administered in combination with nivolumab induced durable response and robust survival outcomes for patients with non-small cell lung cancer who progressed after deriving benefit from treatment with a checkpoint inhibitor and/or platinum doublet chemotherapy.
Blood-based tumor mutational burden does not predict a benefit of first-line atezolizumab over chemotherapy in patients with non–small cell lung cancer.
The triplet combination of umbralisib, ublituximab, and pembrolizumab demonstrated durable responses with a tolerable safety profile in patients with relapsed/refractory chronic lymphocytic leukemia and Richter’s transformation.
Andre H. Goy, MD, discusses the importance of refined decision making with precision medicine.
John L. Marshall, MD, discusses the importance of molecular profiling when utilizing precision medicine.
Benjamin P. Levy, MD, discusses potential strategies to overcome resistance to osimertinib in EGFR-mutant non–small cell lung cancer.
William G. Wierda, MD, PhD, discusses the fixed-duration cohort results of the phase 2 CAPTIVATE trial in chronic lymphocytic leukemia.
Sikander Ailawadhi, MD, discusses the results of a first-in-human, early phase 1 study of lisaftoclax in patients with hematologic malignancies.
A genome-wide look into changes in three-dimensional chromatin organization between ibrutinib-resistant and parental chronic lymphocytic leukemia cells illustrated the involvement of PAK1 as an oncogenic driver in CLL.
Baseline tumor immunogenicity may be associated with higher pathologic complete response rates and favorable outcomes in hormone receptor-positive, HER2-positive early stage breast cancer when comparing de-escalated neoadjuvant ado-trastuzumab emtansine with or without endocrine therapy, vs trastuzumab plus endocrine therapy.
Zanubrutinib monotherapy showed a deepening of response in patients with relapsed/refractory chronic lymphocytic leukemia.
Adjuvant treatment with atezolizumab led to an improvement in disease-free survival and time to locoregional and distant relapse compared with best supportive care in prespecified subgroups of PD-L1–positive patients with stage II to IIIA NSCLC, according to exploratory findings from the phase 3 IMpower010 trial.
First-line sunitinib was found to improve efficacy compared with placebo in patients with malignant pheochromocytoma and paragangliomas.
TG-1701, a covalently bound BTK inhibitor, used as monotherapy or in combination with umbralisib and ublituximab, demonstrated promising activity and a manageable safety profile in patients with chronic lymphocytic leukemia.
Lisocabtagene maraleucel in combination with ibrutinib was associated with manageable safety for patients with relapsed or refractory chronic lymphocytic leukemia or small lymphocytic lymphoma, according to updated data from the phase 1 TRANSCEND-CLL-004 trial.
Clinical limit of detection may be a reasonable metric for evaluating cell-free DNA for multi-cancer early detection.
The anti-PD-1 antibody balstilimab in combination with the anti-CTLA-4 antibody zalifrelimab exhibited impressive response rates, duration of response, and overall survival in patients with previously treated recurrent/metastatic cervical cancer.
Jason J. Luke, MD, FACP, discusses the results of the phase 3 KEYNOTE-716 trial in high-risk stage II melanoma.
